Subtitles section Play video
-
AstraZeneca said Monday that a coronavirus vaccine is developing with the University of Oxford produces an immune response in both the elderly and the young.
-
The UK drugmaker also said that adverse reactions were lower among the elderly, Britain's Financial Times newspaper reported The vaccine triggers protective antibodies on T cells in older age groups.
-
T cell immunity is thought to be essential to protection against infection from the virus and could provide longer term immunity than antibodies.
-
Blood tests carried out on a set of older participants reflected data released in July which showed the vaccine did generate quote robust immune responses in healthy adults aged 18 to 55.
-
AstraZeneca said that it was encouraging to see the immune responses were similar between both older and younger adults.
-
They also claimed the results further built the body of evidence for the safety and effectiveness of their drug.
-
AstraZeneca has worked with University of Oxford researchers this year on a vaccine, and it's seen as a global front runner in the race to produce one.
-
British Health Secretary Matt Hancock said a vaccine was not yet ready, but he was preparing logistics for a possible rollout.
-
He added he expected this to happen in the first half of 2021.
-
Astra Zeneca shares rose around nor 20210.8% in early trade Monday, defying a down day for broader markets.